ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Exploration of the Mechanism of Lianhua Qingwen in Treating Influenza Virus Pneumonia and New Coronavirus Pneumonia with the Concept of "Different Diseases with the Same Treatment" Based on Network Pharmacology

Su, Huihui*; Wu, Guosong; Zhan, Lulu; Xu, Fei; Qian, Huiqin; Li, Yanling; Zhu, Ximei*南方医科大学
Evidence-based Complementary and Alternative Medicine2022-2-8DOI: 10.1155/2022/5536266
7被引19阅读
引用收藏
分享

摘要

The 31 main components of Lianhua Qingwen (LHQW) were obtained through a literature and database search; the components included glycyrrhizic acid, emodin, chlorogenic acid, isophoroside A, forsythia, menthol, luteolin, quercetin, and rutin. Sixty-eight common targets for the treatment of novel coronavirus pnewnonia (NCP) and influenza virus pneumonia (IVP) were also obtained. A "component-target-disease" network was constructed with Cytoscape 3.2.1 software, and 20 key targets, such as cyclooxygenase2 (COX2), interleukin-6 (IL-6), mitogen-activated protein kinase14 (Mapk14), and tumor necrosis factor (TNF), were screened from the network. The David database was used to perform a Kyoto Encyclopedia of Genes and Genomes (KEGG) signal pathway enrichment analysis and gene ontology (GO) biological process enrichment. Results showed that the key targets of LHQW in the treatment of NCP and NP mainly involved biological processes, such as immune system process intervention, cell proliferation, apoptosis and invasion, toxic metabolism, cytokine activity, and regulation of the synthesis process. KEGG enrichment analysis revealed that 115 signalling pathways were related to the treatment of LHQW. Amongst them, IL-17, T cell receptor, Th17 cell differentiation, TNF, toll-like receptor, MAPK, apoptosis, and seven other signalling pathways were closely related to the occurrence and development of NCP and IVP. Molecular docking showed that each component had different degrees of binding with six targets, namely, 3C-like protease (3CL), angiotensin-converting enzyme 2 (ACE2), COX2, hemagglutinin (HA), IL-6, and neuraminidase (NA). Rutin, isoforsythiaside A, hesperidin and isochlorogenic acid B were the best components for docking with the six core targets. The first five components with the best docking results were isoforsythiaside, hesperidin, isochlorogenic acid B, forsythin E, and quercetin. In conclusion, LHQW has many components, targets, and pathways. The findings of this work can provide an important theoretical basis for determining the mechanism of LHQW in treating NCP and IVP.

学科与关键词

关键词
NF-KAPPA-BINTERLEUKIN-17COVID-19BLOCKINGPATHWAY
相关
加载中…
  • Exploring the Potential Targets and Mechanisms of Huang Lian Jie Du Decoction in the Treatment of Coronavirus Disease 2019 Based on Network Pharmacology
    Liu, Wang; Zeng, Yu; Li, Yanda; Li, Nanhong; Peng, Min; Cheng, Junfen; Tian, Binbin*; Chen, Mingdi*International Journal of General Medicine, 2021, 14: 9873-9885.被引 6
  • Network pharmacology and molecular docking to scientifically validate the potential mechanism of Lonicerae japonicae flos in the clinical treatment of COVID-19
    Huang, Yisheng*; Fang, Yan; Jie, Huanhuan; Yang, Hongbiao; Zhou, Wen; Chen, Yijian; Zhong, Baolin*NATURAL PRODUCT RESEARCH, 2023.
  • Identification of phytochemicals in Qingfei Paidu decoction for the treatment of coronavirus disease 2019 by targeting the virus-host interactome
    Li, Yuyun; Wu, Yan; Li, Siyan; Li, Yibin; Zhang, Xin; Shou, Zeren; Gu, Shuyin; Zhou, Chenliang; Xu, Daohua; Zhao, Kangni; Tan, Suiyi; Qiu, Jiayin*; Pan, Xiaoyan*; Li, Lin*Biomedicine and Pharmacotherapy, 2022, 156: 113946.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
Evidence-based Complementary and Alternative Medicine
发表日期
2022-02-08
卷期
第 2022 卷
页码
5536266
DOI
10.1155/2022/5536266
语言
ENGLISH
期刊等级
4区
成果收录
SCIE
资助标注
Universitylevel application project of Xinxiang Medical University [XJKT201920]; Program for Training Key Teachers of Sanquan College of Xinxiang Medical University [SQ2021GGJS05]; Science and Technology Bureau Project of Huadu District [21-HDWS-109]

作者

  • S

    Su, Huihui (通讯) (第一作者)

    xinxiang med univ

  • W

    Wu, Guosong

    southern med univ

查看全部 7 位作者收起作者
  • Z

    Zhan, Lulu

    xinxiang med univ

  • X

    Xu, Fei

    xinxiang med univ

  • Q

    Qian, Huiqin

    xinxiang med univ

  • L

    Li, Yanling

    xinxiang med univ

  • Z

    Zhu, Ximei (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417